Microbial contamination of hematopoietic progenitor cell products: clinical outcome

Area of Science:

• Hematology
• Microbiology
• Transplantation Science

Background:

• Hematopoietic progenitor cell (HPC) transplantation is a critical therapy for various hematologic malignancies and other diseases.
• Ensuring the microbiological safety of HPC products is paramount to prevent infectious complications in immunocompromised patients.

Purpose of the Study:

• To assess the frequency of microbial contamination in infused HPC products.
• To evaluate the clinical outcomes of patients who received contaminated HPC products, particularly in relation to antibiotic prophylaxis.

Main Methods:

• Review of routine microbiological assay results for 3078 infused HPC products (autologous and allogeneic) from January 2001 to December 2005.
• Analysis of infection rates and clinical sequelae in patients who received contaminated products, correlating with empirical antibiotic prophylaxis.

Main Results:

• A low rate of microbial contamination (1.2%, 37 products) was identified in infused HPC products.
• Coagulase-negative Staphylococcus was the most common contaminant (86.5%).
• No patients receiving contaminated infusions developed positive blood cultures, attributable infections, or clinical sequelae, owing to antibiotic prophylaxis.

Conclusions:

• Microbial contamination of HPC products occurs infrequently.
• Empirical antibiotic prophylaxis guided by microbiological assay results is an effective strategy to prevent clinical complications from contaminated HPC infusions.
• The safety and efficacy of HPC transplantation are maintained through vigilant microbiological monitoring and appropriate prophylactic measures.